Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF) with AI Score 43/100 (Weak). Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a Chinese pharmaceutical company involved in the research, development, manufacture, and sale of medicines and healthcare products. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF) Healthcare & Pipeline Overview
Guangzhou Baiyunshan Pharmaceutical Holdings operates in the specialty and generic drug manufacturing sector, focusing on both traditional Chinese medicine and Western medicine. With a diverse portfolio spanning pharmaceuticals, healthcare products, and retail pharmacies, the company leverages its established presence in the Chinese market and international reach to drive growth.
Investment Thesis
Guangzhou Baiyunshan Pharmaceutical Holdings presents a mixed investment case. The company's diverse product portfolio and established retail network in China provide a stable revenue base, reflected in its $5.93 billion market cap and a dividend yield of 3.13%. However, a relatively low profit margin of 3.9% and gross margin of 16.6% indicate potential challenges in operational efficiency and pricing power. The company's low beta of 0.29 suggests lower volatility compared to the broader market. Upcoming growth catalysts include expansion of its healthcare services and product lines. Investors should closely monitor the company's ability to improve profitability and navigate regulatory changes in the Chinese pharmaceutical market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $5.93 billion indicates a substantial presence in the pharmaceutical market.
- P/E ratio of 13.94 suggests a potentially undervalued stock compared to industry peers.
- Dividend Yield of 3.13% offers an attractive income stream for investors.
- Gross Margin of 16.6% reflects the company's profitability after accounting for the cost of goods sold.
- Beta of 0.29 indicates lower volatility compared to the broader market, potentially making it a more stable investment.
Competitors & Peers
Strengths
- Diverse product portfolio including both Chinese and Western medicines.
- Extensive retail pharmacy network across China.
- Established brand reputation and market presence.
- Integrated operations across the pharmaceutical value chain.
Weaknesses
- Relatively low profit margin compared to industry peers (3.9%).
- Dependence on the Chinese market.
- Limited international presence compared to global pharmaceutical companies.
- Potential vulnerability to regulatory changes in the pharmaceutical industry.
Catalysts
- Upcoming: Expansion of healthcare services targeting the aging population in China.
- Upcoming: Development and launch of new pharmaceutical products and therapies.
- Ongoing: Increasing market penetration in existing geographic regions.
- Ongoing: Strategic partnerships and acquisitions to expand product portfolio and market reach.
Risks
- Potential: Increasing competition from domestic and international pharmaceutical companies.
- Potential: Regulatory changes impacting drug pricing and market access in China.
- Potential: Patent expirations and generic competition.
- Ongoing: Economic slowdown in China affecting consumer spending on healthcare products.
Growth Opportunities
- Expansion of Healthcare Services: Guangzhou Baiyunshan's investment in healthcare services, including medical care, health management, and elderly care, represents a significant growth opportunity. As China's population ages, the demand for these services is expected to increase substantially. The company can leverage its existing infrastructure and expertise to capture a larger share of this market, potentially increasing revenue by 15-20% over the next three years.
- New Product Development and Innovation: Investing in research and development to create new pharmaceutical products and healthcare solutions can drive future growth. Focusing on innovative treatments and therapies can differentiate Guangzhou Baiyunshan from its competitors and attract new customers. Successful development and commercialization of new products could lead to a 10-15% increase in revenue within five years.
- Geographic Expansion: Expanding its retail pharmacy network and distribution channels to new regions within China and internationally can significantly increase Guangzhou Baiyunshan's market reach. Targeting underserved markets and establishing strategic partnerships can accelerate this expansion. This expansion could contribute to a 10% annual revenue growth over the next five years.
- Strategic Acquisitions and Partnerships: Acquiring smaller pharmaceutical companies or forming strategic partnerships with other industry players can provide access to new technologies, products, and markets. These acquisitions can enhance Guangzhou Baiyunshan's competitive position and drive synergistic growth. Successful integration of acquired companies could boost overall revenue by 8-12% within three years.
- Digital Transformation and E-commerce: Investing in digital technologies and expanding its e-commerce presence can improve operational efficiency, enhance customer engagement, and drive online sales. Developing a user-friendly online platform and leveraging data analytics can personalize customer experiences and optimize marketing efforts. This digital transformation could lead to a 10% increase in online sales within two years.
Opportunities
- Expanding healthcare services to capitalize on the aging population.
- Developing new and innovative pharmaceutical products.
- Increasing its presence in the international market.
- Leveraging digital technologies to enhance customer engagement and operational efficiency.
Threats
- Increasing competition from domestic and international pharmaceutical companies.
- Potential regulatory changes impacting drug pricing and market access.
- Patent expirations and generic competition.
- Economic slowdown in China affecting consumer spending on healthcare products.
Competitive Advantages
- Established brand reputation in the Chinese pharmaceutical market.
- Extensive retail pharmacy network.
- Diverse product portfolio spanning traditional Chinese medicine and Western medicine.
- Vertical integration across the pharmaceutical value chain.
About GZPHF
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, established in 1997 and based in Guangzhou, China, is a comprehensive pharmaceutical company engaged in the research, development, manufacture, and sale of a wide range of pharmaceutical products. These include Chinese patent medicines, Western medicines, chemical raw materials, natural and biological medicines, and intermediates. The company operates through four key segments: Great Southern TCM, focusing on traditional Chinese medicine; Great Commerce, handling wholesale and retail operations; Great Health, concentrating on healthcare products and services; and Others, encompassing investments and other business activities. Guangzhou Baiyunshan has expanded its operations to include the wholesale, retail, import, and export of medicines and medical equipment. It also produces beverages, food, healthcare products, and various pharmaceutical formulations. The company has a significant retail presence, operating 154 retail chain pharmacy outlets as of December 31, 2021, under brands like Cai Zhi Lin, Jian Min, and GPC Prescription Pharmacy. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013.
What They Do
- Researches and develops Chinese patent and Western medicines.
- Manufactures and sells chemical raw materials and biological medicines.
- Engages in the wholesale and retail of Western and Chinese medicines.
- Imports and exports medicines and medical apparatus.
- Produces beverages, food, and healthcare products.
- Invests in health industry, such as medical care and elderly care.
- Provides commercial and advertising services.
Business Model
- Develops, manufactures, and sells pharmaceutical products.
- Operates a network of retail pharmacy outlets.
- Provides healthcare services and invests in health-related industries.
- Generates revenue through product sales, retail operations, and service fees.
Industry Context
Guangzhou Baiyunshan operates in the competitive pharmaceutical industry, facing both domestic and international players. The Chinese pharmaceutical market is experiencing growth driven by an aging population and increasing healthcare spending. The company's focus on both traditional Chinese medicine and Western medicine allows it to cater to a broad consumer base. Competitors include DNPUF (Daiichi Sankyo), HKMPF (China Resources Pharmaceutical Group), HKMPY (Sinopharm Group), HLBBF (LG Chem), and HLUBF (Yuhan).
Key Customers
- Patients and consumers seeking pharmaceutical products and healthcare services.
- Hospitals and medical institutions.
- Retail pharmacies and distributors.
- Healthcare providers and professionals.
Financials
Chart & Info
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF) stock price: Price data unavailable
Latest News
No recent news available for GZPHF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GZPHF.
Price Targets
Wall Street price target analysis for GZPHF.
MoonshotScore
What does this score mean?
The MoonshotScore rates GZPHF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Hong Li
Unknown
Information on Hong Li's background is not available in the provided context. Details regarding his career history, education, and previous roles are unknown. Further research would be required to provide a comprehensive profile.
Track Record: Due to the lack of available information regarding Hong Li's background and experience, it is not possible to assess his track record or highlight key achievements and strategic decisions made under his leadership. Further research is needed to evaluate his performance and contributions to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited.
GZPHF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading volume can be sporadic. Unlike NYSE or NASDAQ listings, OTC Other stocks do not have to adhere to strict listing requirements, potentially increasing investment risks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Disclosure: OTC Other companies often have minimal financial reporting requirements, making it difficult to assess their financial health and performance.
- Low Liquidity: Low trading volumes can lead to price volatility and difficulty in executing trades.
- Regulatory Scrutiny: OTC stocks are subject to less regulatory oversight compared to exchange-listed stocks, increasing the risk of fraud and manipulation.
- Information Asymmetry: Limited information available to investors can create an uneven playing field and increase the risk of making uninformed investment decisions.
- Going Concern Risk: Companies trading on the OTC Other market may face financial difficulties or have a higher risk of bankruptcy.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Monitor trading volume and price volatility.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established Business Operations: The company has been in operation since 1997.
- Diverse Product Portfolio: The company offers a wide range of pharmaceutical products and healthcare services.
- Retail Pharmacy Network: The company operates a network of retail pharmacy outlets.
- International Operations: The company engages in international trade.
What Investors Ask About Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF)
What does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited do?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a comprehensive pharmaceutical company that researches, develops, manufactures, and sells a wide range of pharmaceutical products, including traditional Chinese medicines and Western medicines. It operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. The company also operates a network of retail pharmacy outlets and invests in healthcare services, such as medical care and elderly care, providing commercial and advertising services.
What do analysts say about GZPHF stock?
AI analysis for GZPHF is currently pending. Without analyst consensus, key valuation metrics, and growth considerations are unavailable. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. Factors to consider include the company's financial performance, competitive landscape, and regulatory environment.
What are the main risks for GZPHF?
The main risks for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited include increasing competition from domestic and international pharmaceutical companies, potential regulatory changes impacting drug pricing and market access in China, patent expirations and generic competition, and the impact of an economic slowdown in China on consumer spending on healthcare products. Additionally, as an OTC-listed company, GZPHF faces risks related to limited disclosure, low liquidity, and regulatory scrutiny.
What are the key factors to evaluate for GZPHF?
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF) currently holds an AI score of 43/100, indicating low score. Key strength: Diverse product portfolio including both Chinese and Western medicines.. Primary risk to monitor: Potential: Increasing competition from domestic and international pharmaceutical companies.. This is not financial advice.
How frequently does GZPHF data refresh on this page?
GZPHF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GZPHF's recent stock price performance?
Recent price movement in Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse product portfolio including both Chinese and Western medicines.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GZPHF overvalued or undervalued right now?
Determining whether Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GZPHF?
Before investing in Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.
- AI analysis is pending and may provide additional insights.